Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the abrysvo or arexvy market grown in recent years?

In the past few years, the abrysvo or arexvy market has experienced an HCAGR of XX. The market size is projected to escalate from $XX million in 2024 to $XX million in 2025, indicating a compound annual growth rate (CAGR) of XX%. The notable growth during the historic era can be linked to a variety of factors such as an increasing elderly population, the launch of vaccination initiatives, amplified consciousness about respiratory diseases, health programs spearheaded by the government, and the prevalence of periodic respiratory disease epidemics.

How is the abrysvo or arexvy market size expected to evolve during the forecast period?

Expectations are high for the abrysvo or arexvy market size as it is projected to witness an XX (FCAGR) in the coming years. It’s predicted to inflate to a dizzying $XX million in 2029, with a compound annual growth rate (CAGR) of XX%. Factors such as the rising elderly population, augmented availability and widespread distribution of vaccines, heightened focus on preventive healthcare, a surging number of respiratory infections, and enhancements in healthcare policies and coverage could drive this growth during the forecast period. The upcoming period is also likely to see major trends such as advancements in vaccine technology, the advent of personalized medicine, integration of wearable health technology, innovations in vaccine delivery, development in cold chain logistics, and progress in smart packaging.

Get your abrysvo or arexvy market report here!

https://www.thebusinessresearchcompany.com/report/abrysvo-or-arexvy-global-market-report

Which key drivers are propelling the abrysvo or arexvy market’s growth?

The escalating occurrence of respiratory syncytial virus (RSV) infections is projected to further fuel the expansion of the abrysvo or arexvy market. RSV infections, initiated by the respiratory syncytial virus, primarily affect the respiratory system and generally result in mild, cold-like symptoms. However, the virus can lead to severe diseases in infants, older people, and those with weakened immune systems. The growing incidence of RSV infections can be attributed to its highly infectious nature, periodic outbreaks, lack of widespread immunity, and heightened vulnerability among susceptible groups such as the elderly and infants. Abrysvo offers an effective solution to these infections by offering vaccines specifically designed to shield high-risk groups like older people and infants from serious illnesses related to the respiratory syncytial virus. For example, data from the US-based health protection organization, the Centers for Disease Control and Prevention, revealed that in October 2024, the total rate of hospitalizations linked to RSV surged to 3.2 per 100,000 people during the 2024-25 season. Thus, the rising occurrence of RSV infections bolsters the abrysvo or arexvy market’s expansion.

What are the market segments in the abrysvo or arexvy industry?

The abrysvo or arexvy market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection

2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)

3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19948&type=smp

Which leading companies are shaping the growth of the abrysvo or arexvy market?

Major companies operating in the abrysvo or arexvy market include Pfizer Inc.; GlaxoSmithKline plc (GSK)

What key trends are currently impacting the abrysvo or arexvy market’s development?

The principal trend emerging in the abrysvo or arexvy market revolves around enhancing age indications to extend the use of the vaccine to a broader age demographic, thereby amplifying public health safety and enlarging market success. The bivalent RSV prefusion F (RSVpreF) vaccine is specialized to offer immunity against the respiratory syncytial virus (RSV), which aims at both RSV-A and RSV-B subtypes. For instance, in October 2024, Pfizer Inc., an American pharmaceutical corporation, obtained FDA approval for ABRYSVO (RSV Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine. This vaccine is intended to prevent lower respiratory tract diseases in adults aged 18 to 59 who are at heightened risk, expanding its usage to the widest adult population. Uniquely, it is the only approved RSV vaccine for expectant women between 32 and 36 weeks of gestation to shield infants from birth up to 6 months.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19948

Which geographic areas are influencing the growth of the abrysvo or arexvy market?

North America was the largest region in the abrysvo or arexvy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Respiratory Disease Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Pertussis Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Influenza A Virus Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/h1n1-vaccine-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: